An error occurred retrieving publication content to display, please try again.
Page not found (404)
Sorry - the page you requested could not be found.
Please choose a page from the navigation or try a website search above to find the information you need.
Toolkit
There was evidence that the treatment period risks varied with the medication, but buprenorphine as an alternative to methadone may not reduce mortality overall due to shorter treatment duration.
1 Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
2 National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
3 Centre for Mental Health and Safety, School of Health Sciences, University of Manchester, Manchester, UK
4 Bristol Drug Project, Bristol, UK
5 Department of Mathematics and Statistics, The Open University, Milton Keynes, UK
* Corresponding author Email: Colin.Steer@bristol.ac.uk
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
Report Content
The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Responses to this report
No responses have been published.
An error has occurred in processing the XML document